Thursday, February 9, 2012 Last update: 2:04 PM
The Best of U.S. Company Technology News
Now being accepted at FreshNews.com. See our complete guidelines.
Trade Events
Acorda Therapeutics, Inc.
News articles for Acorda Therapeutics, Inc.:
Thursday, February 9, 2012
- Acorda Therapeutics to Present at Leerink Swann 2012 Global Healthcare ConferenceAcorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the Leerink Swann 2012 Global Healthcare Conference on Thursday, February 16, ... read more
Friday, February 3, 2012
- Acorda Therapeutics Presents Preclinical Data Showing Dalfampridine Improves Motor Function in Chronic StrokeAcorda Therapeutics, Inc. (Nasdaq: ACOR) presented data showing that treatment with dalfampridine improved motor function in a preclinical model of stroke, with treatment initiated at ... read more
Monday, January 9, 2012
- Acorda Therapeutics Provides 2012 Corporate Update at 30th Annual J.P. Morgan Healthcare ConferenceAcorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2011 were ... read more
Wednesday, December 28, 2011
- Acorda Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare ConferenceAcorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the 30th Annual J.P. Morgan Healthcare Conference on Monday, January 9, ... read more
Tuesday, November 22, 2011
- Acorda Therapeutics to Present at the Piper Jaffray 23rd Annual Healthcare ConferenceAcorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the Piper Jaffray 23rd Annual Healthcare Conference on Tuesday, November 29, ... read more
Wednesday, November 16, 2011
- Acorda Therapeutics Announces Preclinical Data on GGF2 in Heart Failure Presented at American Heart Association Scientific Sessions 2011Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that preclinical data from a study of its investigational drug Glial Growth Factor 2 (GGF2) showed GGF2 ... read more
Tuesday, November 8, 2011
- Acorda Therapeutics to Present at the Lazard Capital Markets 8th Annual Healthcare ConferenceAcorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the Lazard Capital Markets 8th Annual Healthcare Conference on Tuesday, November ... read more
Friday, November 4, 2011
- Acorda Therapeutics Reports Third Quarter 2011 Financial ResultsAcorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the third quarter ended September 30, 2011. ... read more
Monday, September 12, 2011
- Acorda Therapeutics to Present at the UBS Global Life Sciences ConferenceAcorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the UBS Global Life Sciences Conference on Monday, September 19, 2011 ... read more
Wednesday, September 7, 2011
- Acorda Therapeutics Statement on ZANAFLEX CAPSULES® Patent LitigationAcorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. District Court for the District of New Jersey has ruled against it in its patent litigation against Apotex ... read more
Monday, August 15, 2011
- Acorda Therapeutics Joins NY BioHud Valley as Founding MemberAcorda Therapeutics, Inc. (Nasdaq: ACOR), a biotechnology company that develops and commercializes novel therapies to improve, repair or restore function in people with neurological disorders, has joined ... read more